FDA Approves MagVenture TMS Therapy As Adjunct Treatment For Obsessive Compulsive Disorder

On August 11, 2020, MagVenture, Inc. reported that the U.S. Food and Drug Administration (FDA) cleared its transcranial magnetic stimulation (TMS) therapy device for adjunct treatment of obsessive-compulsive disorder (OCD). MagVenture TMS Therapy® can be combined in outpatient treatment with existing OCD therapies, such as pharmaceutical and behavioral therapy. In 2018, the FDA cleared the Brainsway TMS device as adjunct treatment for OCD.

The new therapy for OCD uses a new Cool D-B80 magnetic coil, used in conjunction with the existing MagVenture TMS Therapy® unit. The coil is specifically designed to reach deeper cortical structures in the . . .